X-Zell Revenue and Competitors

Location

N/A

Total Funding

Analytics

Industry

Estimated Revenue & Valuation

  • X-Zell's estimated annual revenue is currently $1.6M per year.(i)
  • X-Zell's estimated revenue per employee is $84,000

Employee Data

  • X-Zell has 19 Employees.(i)
  • X-Zell grew their employee count by 6% last year.

X-Zell's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$73.6M4141%$134MN/A
#2
$4.4M39N/AN/AN/A
#3
$5.6M50N/AN/AN/A
#4
$9.2M73N/AN/AN/A
#5
$0.4M6N/AN/AN/A
#6
$5.4M48N/AN/AN/A
#7
$1.2M14N/AN/AN/A
#8
$10.9M78N/AN/AN/A
#9
$6.7M53-2%N/AN/A
#10
$0.4M5-17%N/AN/A
Add Company

What Is X-Zell?

X-ZELL is a global med tech start-up specialising in the isolation, digitisation and AI-guided analysis of atypical cells won from small, 8-10mL blood samples. Using a suite of patented and proprietary technologies that can be plugged into a standard pathology lab, X-ZELL's breakthrough came in 2017 when we found a way to routinely locate tumour-associated Circulating Endothelial Cells (tCEC) in whole blood. Known to be powerful biomarkers for the early detection of clinically significant cancers, tCEC were long considered ‘undetectable' in clinical routine. X-ZELL overcame that long-standing impasse by fusing next-generation multiplexing with cryo-technology and Artificial Intelligence – empowering scientists to identify a single tCEC among more than 5 billion healthy blood cells and visualise it on screen with never-before-seen clarity. Backed by Y Combinator, international angel investors as well as institutional investors from both Europe and Asia, X-ZELL went on to develop the world's first tCEC-based blood test for the early detection of clinically significant prostate cancer – X-ZELL™ Prostate. In 2018-19, a blinded, prospective clinical study demonstrated that X-ZELL™ Prostate can safely prevent more than 70 per cent of unnecessary biopsies in high-risk prostate cancer patients, paving the way for a new, pain- and risk-free screening paradigm. The first in a series of targeted liquid biopsies, X-ZELL Prostate™ is already approved for sale in Thailand and will be launched across the ASEAN region following the conclusion of a final, blinded validation study in Singapore. Headquartered in Singapore, X-ZELL's ambition is to make tCEC-based cancer screening accessible to patients around the globe – accurate, affordable and accessible for all. More in-depth information on www.x-zell.com/blog and via our Twitter handle @XZELLInc

keywords:N/A

N/A

Total Funding

19

Number of Employees

$1.6M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

X-Zell News

2022-04-20 - Panaracer announces Limited Edition Ginger and Astral Blue ...

All three models come in 700 x 32c and 700 x 38c. ... Jeff Zell, Panaracer's Global Go-To Guy, says: “This is the 5th year we've offered...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.9M196%N/A
#2
$1.6M196%N/A
#3
$1.5M19N/AN/A
#4
$1.5M19-41%N/A
#5
$1.7M196%N/A